Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

al compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; inability or delay in establishing sales infrastructure to support potential commercialization; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates; and our ability to raise additional capital as needed. For further information regarding these and other risks r
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- R-Japan Co.,Ltd. obtained the license of cell processing facility ... the Ministry of Health, Labour and Welfare Kinki Bureau of ... The fact that R- Japan received the ... and Medical Devices Agency (PMDA) on May 18, 2015 two ... cell manufacturing service to medical institutions. As of November 25, ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix ... of common shares of Resverlogix have approved the ... Eastern Capital Limited of 5,600,000 units at a ... Placement"), each unit being comprised of one common ... aggregate proceeds of approximately CAD$15 million; and (ii) ...
(Date:6/30/2015)...  NASA astronaut Kjell Lindgren , who is making ... mission to the International Space Station , will be ... EDT Tuesday, July 7. Lindgren will participate from ... Russia . The interviews will be preceded at 7:30 ... training. To schedule an interview, media must contact ...
(Date:6/30/2015)... , June 30, 2015  Today, Americord Registry, one of ... Andrew Horne , a partner at Kirkland & Ellis ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We ... Advisory Board," says Martin Smithmyer , CEO of Americord. ... legal career that will assist Americord,s growth and vision." ...
Breaking Biology Technology:R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... for Business Intelligence (CBI) announced today that the company will ... the relief efforts in Japan following a devastating earthquake and ... the organization matched employee donations. "I am so ... to help a nation in a desperate time of need," ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... (Barbados) SRL (VIB), received a commitment in principle to ... U.S., Canada and Mexico.  Terms of the license will ... agreement.  Earlier today Meda announced that it reached a ...
... and engineers, as well as students working in ... curve when developing common MEMS fabrication processes. A ... Springer promises to be an important game-changing asset ... and Processes Handbook is an exhaustive design reference ...
Cached Biology Technology:The Center for Business Intelligence Donates to the American Red Cross, Matching Employee Contributions for Disaster Relief in Japan 2Meda to License Elidel to Valeant Pharmaceuticals 2MEMS Materials and Processes Handbook -- a comprehensive, practical resource 2
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/15/2015)... June 16, 2015 According to ... by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, ... 2020" published by MarketsandMarkets, The Natural Language Processing Market ... CAGR of 18.4% for the forecast period 2015-2020. ... 46 F igures spread   through 155 P ...
(Date:6/11/2015)... Daon, a global leader in mobile ... Mobile Authentication Platform v4.0 has been FIDO Certified™.  ... industry consortium launched in 2013 to revolutionize online ... In order to receive certification, a company,s products ... tests that measure compliance and ensure interoperability among ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... the gene that sets off a sequence of events ... can lead to high blood pressure. The disease process ... of blockages that can cause heart attacks, strokes and ... led by Ohio State University researchers might lead to ...
... treat iron poisoning can significantly boost the bodys own ... researchers at the University of Alabama at Birmingham (UAB). ... is designed to reduce iron overload, into injured mouse ... blood vessels, which in turn kicked off bone re-growth ...
... has shown promising results in fighting a severe genetic disorder ... genetic knowledge have transformed our understanding of disease in recent ... wide variety of conditions. However, so far, very few cures ... Now a UK study led by researchers at Cardiff ...
Cached Biology News:High blood pressure in older adults traced to gene's effects in blood vessels 2High blood pressure in older adults traced to gene's effects in blood vessels 3New treatment boosts bone healing and regrowth 2Genetic breakthrough offers promise in tackling kidney tumors 2
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Slide Chambers are convenient for performing pre-hybridization incubations and post-hybridization washes with tissue sections mounted on standard glass microscope slides. Each chamber holds up to 5 s...
Human peripheral blood PBMCs, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Biology Products: